Functional bowel disorders.

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ (2008) 6.97

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12

Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87

American Gastroenterological Association technical review on constipation. Gastroenterology (2013) 3.27

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut (2013) 3.14

Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One (2010) 3.03

Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut (2015) 2.99

The pathophysiology, diagnosis, and treatment of constipation. Dtsch Arztebl Int (2009) 2.85

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81

Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology (2011) 2.60

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ (2009) 2.51

A treatment trial of acupuncture in IBS patients. Am J Gastroenterol (2009) 2.41

MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut (2009) 2.39

Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol (2009) 2.39

[Definition, classification and diagnosis of fibromyalgia syndrome]. Schmerz (2008) 2.38

Functional bowel disorders in adults. Dtsch Arztebl Int (2012) 2.38

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol (2015) 2.35

Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol (2014) 2.35

The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol (2010) 2.30

Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30

Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder. Pain (2009) 2.30

Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol (2010) 2.23

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2014) 2.17

Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil (2014) 2.11

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol (2012) 2.11

The epidemiology of irritable bowel syndrome. Clin Epidemiol (2014) 2.06

International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol (2009) 2.06

Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol (2010) 2.02

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract (2007) 2.02

Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol (2009) 2.02

Diagnosis and treatment of chronic constipation--a European perspective. Neurogastroenterol Motil (2011) 1.99

Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88

Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil (2012) 1.87

Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain (2009) 1.80

Incidence and risk factors for fecal incontinence in black and white older adults: a population-based study. J Am Geriatr Soc (2010) 1.79

Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol (2009) 1.76

Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology (2010) 1.75

The brain-gut axis in abdominal pain syndromes. Annu Rev Med (2011) 1.68

Review of the treatment options for chronic constipation. MedGenMed (2007) 1.64

Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol (2009) 1.64

Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr (2011) 1.63

Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain (2011) 1.63

An update on the use and investigation of probiotics in health and disease. Gut (2013) 1.62

"Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial. Cult Med Psychiatry (2009) 1.60

Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin North Am (2008) 1.59

Randomised controlled trial of mesalazine in IBS. Gut (2014) 1.58

Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol (2013) 1.57

Irritable bowel syndrome--the main recommendations. Dtsch Arztebl Int (2011) 1.56

Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. Gastroenterology (2015) 1.56

New insights into Blastocystis spp.: a potential link with irritable bowel syndrome. PLoS Pathog (2012) 1.56

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut (2015) 1.55

Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil (2013) 1.55

Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int (2012) 1.54

Predicting persistence of functional abdominal pain from childhood into young adulthood. Clin Gastroenterol Hepatol (2014) 1.53

S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci (2013) 1.52

Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2011) 1.49

Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci (2013) 1.48

Xerophthalmia and acquired night blindness in a patient with a history of gastrointestinal neoplasia and normal serum vitamin A levels. Doc Ophthalmol (2013) 1.48

Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria. Patient Prefer Adherence (2008) 1.46

Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. Dig Dis Sci (2015) 1.46

Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain. Pain (2013) 1.45

Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol (2016) 1.43

The impact of laxative use upon symptoms in patients with proven slow transit constipation. BMC Gastroenterol (2011) 1.43

A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci (2015) 1.43

Perceived risk as a barrier to appropriate diagnosis of irritable bowel syndrome. World J Gastroenterol (2014) 1.42

The association between prucalopride efficacy and constipation type. Tech Coloproctol (2013) 1.42

MR-defecography in obstructed defecation syndrome (ODS): technique, diagnostic criteria and grading. Tech Coloproctol (2013) 1.42

Colon transit time and anorectal manometry in children and young adults with spina bifida. Int J Colorectal Dis (2013) 1.39

Incidence and predictive factors of irritable bowel syndrome after acute diverticulitis in Korea. Int J Colorectal Dis (2014) 1.39

Prevalence and Self-recognition of Chronic Constipation: Results of an Internet Survey. J Neurogastroenterol Motil (2016) 1.38

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci (2007) 1.35

Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35

Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci (2014) 1.34

Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil (2010) 1.33

Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology (2009) 1.33

Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol (2012) 1.32

Text messaging: an innovative method of data collection in medical research. BMC Res Notes (2010) 1.32

Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut (2011) 1.31

Functional bowel disorders in Iranian population using Rome III criteria. Saudi J Gastroenterol (2010) 1.30

Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol (2010) 1.29

Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther (2009) 1.28

Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med (2009) 1.28

What is necessary to diagnose constipation? Best Pract Res Clin Gastroenterol (2011) 1.27

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci (2007) 1.27

The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol (2010) 1.26

The microbiome: stress, health and disease. Mamm Genome (2013) 1.24

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24

Irritable bowel syndrome: is it associated with genotypes of Blastocystis hominis. Parasitol Res (2010) 1.24

Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol (2007) 1.24

The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III. J Neurogastroenterol Motil (2010) 1.24

Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil (2011) 1.23

Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? J Neurogastroenterol Motil (2015) 1.23

Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology (2011) 1.22

Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20

Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. Gut Microbes (2014) 1.19

Current status of functional gastrointestinal evaluation in clinical practice. Singapore Med J (2015) 1.19

Genetic approaches to functional gastrointestinal disorders. Gastroenterology (2010) 1.18

Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.18

The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology (2011) 1.18

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog (2010) 1.17

Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21

An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol (2006) 3.30

Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60

Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology (2003) 2.39

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol (2006) 2.14

First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology (2009) 1.97

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol (2005) 1.93

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol (2003) 1.92

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology (2006) 1.85

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol (2006) 1.83

Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol (2009) 1.73

Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology (2011) 1.70

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol (2002) 1.67

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol (2009) 1.65

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60

Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol (2009) 1.54

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53

Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology (2010) 1.49

Clinical predictors of Barrett's esophagus length. Gastrointest Endosc (2005) 1.45

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39

Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol (2002) 1.39

Serum alanine aminotransferase predicts interventricular septum thickness and left ventricular mass in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2014) 1.39

Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort study. Gut (2011) 1.35

Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut (2012) 1.30

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29

In vivo imaging of intragastric gelation and its effect on satiety in humans. J Nutr (2004) 1.28

Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study. Gut (2010) 1.28

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol (2004) 1.27

Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology (2013) 1.27

Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol (2003) 1.27

The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol (2010) 1.26

Bowel disorders. Am J Gastroenterol (2010) 1.23

The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology (2011) 1.18

Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am (2011) 1.15

Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology (2009) 1.11

Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology (2008) 1.08

Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA (2013) 1.07

Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol (2008) 1.07

Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. Front Pharmacol (2011) 1.06

Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci (2011) 1.06

Ulcerative colitis associated enteritis: is ulcerative colitis always confined to the colon? J Clin Gastroenterol (2004) 1.04

Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol (2006) 1.04

5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. Eur J Gastroenterol Hepatol (2010) 1.04

Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. Am J Physiol Gastrointest Liver Physiol (2009) 1.03

Gastric emptying of three liquid oral preoperative metabolic preconditioning regimens measured by magnetic resonance imaging in healthy adult volunteers: a randomised double-blind, crossover study. Clin Nutr (2009) 1.03

Information assimilation and distribution challenges and goals for real and virtual journals. J Clin Gastroenterol (2005) 1.02

Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol (2009) 1.02

A population-based study of perforated diverticular disease incidence and associated mortality. Gastroenterology (2008) 1.02

Chronic cough: relationship between microaspiration, gastroesophageal reflux, and cough frequency. Chest (2012) 1.01

Improved methods for fMRI studies of combined taste and aroma stimuli. J Neurosci Methods (2006) 1.01

Fiber and functional gastrointestinal disorders. Am J Gastroenterol (2013) 1.00

Irritable bowel syndrome and coeliac disease. Lancet (2002) 0.99

Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol (2012) 0.99

Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol (2003) 0.99

Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut (2013) 0.98

Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol (2008) 0.97

Bowel dysfunction in patients with motor complete spinal cord injury: clinical, neurological, and pathophysiological associations. Am J Gastroenterol (2006) 0.97

Diverticular abscess of the appendix: report of a case and review of the literature. Dis Colon Rectum (2003) 0.96

Bile duct crystals do not contribute to sphincter of Oddi dysfunction. Gastrointest Endosc (2002) 0.95

Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol (2009) 0.95

Enhancement of intragastric acid stability of a fat emulsion meal delays gastric emptying and increases cholecystokinin release and gallbladder contraction. Am J Physiol Gastrointest Liver Physiol (2007) 0.94

Adaptation to Spanish language and validation of the fecal incontinence quality of life scale. Dis Colon Rectum (2006) 0.94

Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother (2009) 0.94

Preventing gastric sieving by blending a solid/water meal enhances satiation in healthy humans. J Nutr (2012) 0.93

The effects of fasting and refeeding with a 'metabolic preconditioning' drink on substrate reserves and mononuclear cell mitochondrial function. Clin Nutr (2010) 0.92

Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics (2002) 0.92

Peptic ulcer disease in patients with chronic liver disease: looking beyond bugs and drugs. Gastrointest Endosc (2005) 0.90

Diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am (2005) 0.89

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther (2008) 0.89

Effect of intragastric acid stability of fat emulsions on gastric emptying, plasma lipid profile and postprandial satiety. Br J Nutr (2008) 0.89

Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol (2008) 0.88

Nausea and vomiting. Gastroenterology (2003) 0.88

Breath tests for gastrointestinal disease: the real deal or just a lot of hot air? Gastroenterology (2007) 0.87

Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells. World J Gastroenterol (2008) 0.86

Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways. Am J Physiol Gastrointest Liver Physiol (2002) 0.85

The A8344G mutation in mitochondrial DNA associated with stroke-like episodes and gastrointestinal dysfunction. Acta Neuropathol (2002) 0.85

Tegaserod does not alter fasting or meal-induced biliary tract motility. Am J Gastroenterol (2004) 0.85

Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol (2004) 0.85

Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord (2009) 0.85

Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter (2003) 0.85

Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol (2002) 0.85

Abnormal immune regulation and low-grade inflammation in IBS: does one size fit all? Am J Gastroenterol (2012) 0.85

The cortical response to the oral perception of fat emulsions and the effect of taster status. J Neurophysiol (2011) 0.85

The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexes. Cough (2013) 0.85

Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol (2013) 0.85

Clostridial aortitis and colon cancer. Gastrointest Endosc (2004) 0.84

Estimating the importance of infection in IBS. Am J Gastroenterol (2003) 0.83

Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities. Clin Gastroenterol Hepatol (2008) 0.82

Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy? Curr Treat Options Gastroenterol (2014) 0.81

GERD-related cough: pathophysiology and diagnostic approach. Curr Gastroenterol Rep (2011) 0.81

Long-lasting effect of a single botulinum toxin injection in the treatment of oropharyngeal dysphagia secondary to upper esophageal sphincter dysfunction: a pilot study. Scand J Gastroenterol (2008) 0.81

Irritable bowel syndrome and gluten sensitivity without celiac disease: separating the wheat from the chaff. Gastroenterology (2012) 0.81

Erosive esophagitis and NERD: Can we really classify patients with heartburn by endoscopic findings? Clin Gastroenterol Hepatol (2004) 0.80

Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am (2011) 0.80

Number of responses on a review of systems questionnaire predicts the diagnosis of functional gastrointestinal disorders. J Clin Gastroenterol (2003) 0.79

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trials (2013) 0.79